Eli Lilly and Company Reports $303M In Q3 2026 Special Charges, Bringing 9-Month Total To $1.3B, Primarily Driven By Intangible Asset Impairment, Acquisition Costs And Litigation

Note 5: Asset Impairment, Restructuring, and Other Special Charges

Asset impairment, restructuring, and other special charges recognized during the three and nine months ended September 30, 2026 were $303 million and $1.3 billion, respectively. The charges recognized in the three and nine months ended September 30, 2026 related to a partial impairment of an intangible asset associated with a molecule in development. In addition, charges recognized in the nine months ended September 30, 2026 included charges related to acquisition and integration costs associated with the closing of our acquisitions and charges related to litigation matters.

Asset impairment, restructuring, and other special charges recognized during the three and nine months ended September 30, 2025 were $365 million and $400 million, respectively, primarily related to a litigation charge and acquisition and integration costs associated with the closing of our acquisitions.